Tango Therapeutics
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Visit website
LLY Eli Lilly and Company |
$1405.05 | -1.86% |
JNJ Johnson & Johnson |
$278.81 | -1.32% |
ABBV AbbVie |
$291.97 | -0.88% |
MRK Merck & Co. |
$143.42 | -0.72% |
UNH UnitedHealth Group Incorp… |
$388.07 | -5.81% |